Sarah Sammons, Breast Medical Oncologist and Senior Physician at Dana-Farber’s Breast Oncology Center, shared a post by Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, Visiting Professor at McGill University, on X, adding:
“Finally, such a paradigm shifting trial for ER+, HER2+ breast cancer!”
Quoting Paolo Tarantino‘s post:
“PATINA is now out in NEJM.
Among patients with HR+/HER2+ MBC progression-free after chemotherapy induction, adding Palbociclib to 1L ET+HER2-blockade maintenance prolonged PFS from 29 months to an astonishing 44 months (HR 0.75, p=0.02).
Congrats Otto Metzger and coauthors!”
Title: Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Authors: Otto Metzger, Sumithra Mandrekar, Shom Goel, Joseph Gligorov, Elgene Lim, Eva Ciruelos, Sibylle Loibl, Lisa A. Carey
More posts featuring Paolo Tarantino.